Journal Article

BORN study: a multicenter randomized trial investigating cord blood red blood cell transfusions to reduce the severity of retinopathy of prematurity in extremely low gestational age neonates

Cloclite, Eleonora, Pucci, Giulia, Palluzzi, Fernando, Giacò, Luciano, Beccastrini, Enrico, Orlando, Nicoletta, Accorsi, Patrizia, Papacci, Patrizia, Bonfini, Tiziana, Santodirocco, Michele, Ansaldi, Giulia, Fabbri, Marco, Teofili, Luciana, Valentini, Caterina Giovanna, Mondello, Isabella, Mozzetta, Iolanda, Cresi, Francesco, Vento, Giovanni, Santosuosso, Michela, Pasciuto, Tina, Bianchi, Maria, Remaschi, Giulia, Raffaeli, Genny, Dragonetti, Antonella, Villa, Stefania, Giannantonio, Carmen, Ghirardello, Stefano

2022

Overview

Background Extremely low gestational age neonates (ELGANs, i.e., neonates born before 28 weeks of gestation) are at high risk of developing retinopathy of prematurity (ROP), with potential long-life visual impairment. Due to concomitant anemia, ELGANs need repeated red blood cell (RBC) transfusions. These produce a progressive replacement of fetal hemoglobin (HbF) by adult hemoglobin (HbA). Furthermore, a close association exists between low levels of HbF and severe ROP, suggesting that a perturbation of the HbF-mediated oxygen release may derange retinal angiogenesis and promote ROP. Methods/design BORN (umBilical blOod to tRansfuse preterm Neonates) is a multicenter double-blinded randomized controlled trial in ELGANs, to assess the effect of allogeneic cord blood RBC transfusions (CB-RBCs) on severe ROP development. Recruitment, consent, and randomization take place at 10 neonatology intensive care units (NICUs) of 8 Italian tertiary hospitals. ELGANs with gestational age at birth comprised between 24+0 and 27+6 weeks are randomly allocated into two groups: (1) standard RBC transfusions (adult-RBCs) (control arm) and (2) CB-RBCs (intervention arm). In case of transfusion need, enrolled patients receive transfusions according to the allocation arm, unless an ABO/RhD CB-RBC is unavailable. Nine Italian public CB banks cooperate to make available a suitable amount of CB-RBC units for all participating NICUs. The primary outcome is the incidence of severe ROP (stage 3 or higher) at discharge or 40 weeks of postmenstrual age, which occurs first. Discussion BORN is a groundbreaking trial, pioneering a new transfusion approach dedicated to ELGANs at high risk for severe ROP. In previous non-randomized trials, this transfusion approach was proven feasible and able to prevent the HbF decrease in patients requiring multiple transfusions. Should the BORN trial confirm the efficacy of CB-RBCs in reducing ROP severity, this transfusion strategy would become the preferential blood product to be used in severely preterm neonates. Trial registration ClinicalTrials.gov NCT05100212. Registered on October 29, 2021

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Anemia, Neonatal - diagnosis / Anemia, Neonatal - prevention & control / Biomedicine / Blood / Blood transfusion / Blood transfusions / Care and treatment / Clinical trials / Development and progression / Disease prevention / Erythrocyte Transfusion - adverse effects / Extremely low gestational age neonates / Eye diseases / Fetal Blood / Fetal hemoglobin / Gestational Age / Health aspects / Health Sciences / Hemoglobin / Humans / Hypotheses / Infant / Infant, Low Birth Weight / Infant, Newborn / Infant, Premature / Medicine / Medicine & Public Health / Mortality / Newborn babies / Premature babies / Premature birth / Randomized controlled trial / Retinopathy of prematurity / Retinopathy of Prematurity - diagnosis / Retinopathy of Prematurity - prevention & control / Retrolental fibroplasia / Risk factors / Statistics for Life Sciences / Stem cells / Study Protocol / Testing / Transfusions / Umbilical blood / Umbilical cord / Values